low - Dialysis and chronic kidney disease treatment is non-discretionary healthcare with minimal GDP correlation. Patient volumes driven by diabetes/hypertension prevalence and aging demographics rather than economic cycles. However, IBS-C segment (IBSRELA) shows moderate sensitivity as patients may delay non-critical GI treatments during recessions.

Rising rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for unprofitable growth biotech stocks, particularly impacting P/S multiples which expanded during 2020-2021 zero-rate environment; (2) Increased financing costs if company needs to raise additional capital before reaching profitability, though current 4.41x current ratio provides substantial liquidity buffer. Rates do not materially affect underlying business operations as revenue is prescription-driven, not financing-dependent.

growth - Attracts biotech growth investors focused on commercial-stage companies transitioning to profitability. The 168% revenue growth, 85% gross margins, and large addressable market appeal to momentum investors, while negative earnings and cash flow deter value investors. High short interest typical of unprofitable biotechs creates volatility around earnings and clinical catalysts. Not suitable for income investors given no dividend and cash consumption.